News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
253,450 Results
Type
Article (13603)
Company Profile (202)
Press Release (239645)
Section
Business (78784)
Career Advice (143)
Deals (13151)
Drug Delivery (26)
Drug Development (50031)
Employer Resources (31)
FDA (5582)
Job Trends (5093)
News (143026)
Policy (10004)
Tag
Academia (897)
Africa (145)
Alabama (22)
Allergies (28)
Alliances (21322)
ALS (13)
Alzheimer's disease (646)
Antibody-drug conjugate (ADC) (27)
Approvals (5556)
Artificial intelligence (19)
Asia (16481)
Australia (2744)
Bankruptcy (96)
Best Places to Work (4272)
Biosimilars (14)
Breast cancer (13)
C2C Services and Suppliers (10603)
California (479)
Canada (175)
Cancer (87)
Career advice (127)
CAR-T (24)
Cell therapy (49)
China (17)
Clinical research (38550)
Collaboration (35)
Colorado (16)
COVID-19 (961)
Cystic fibrosis (56)
Diabetes (11)
Diagnostics (1131)
Drug pricing (17)
Duchenne muscular dystrophy (14)
Earnings (27843)
Employer resources (29)
Europe (35340)
Events (45228)
Executive appointments (16)
FDA (5582)
Florida (34)
Funding (22)
Gene editing (16)
Gene therapy (46)
GLP-1 (237)
Government (1040)
Healthcare (6478)
Hotbed/Location (184142)
Idaho (14)
Infectious disease (964)
Inflammatory bowel disease (74)
Interviews (15)
IPO (7089)
Job creations (855)
Job search strategy (123)
Layoffs (169)
Legal (1363)
Liver cancer (23)
Lung cancer (16)
Manufacturing (13)
Maryland (15)
Massachusetts (240)
Medical device (2498)
Medtech (2498)
Mergers & acquisitions (5983)
Metabolic disorders (70)
Neuroscience (698)
New Jersey (24)
New York (25)
NextGen Class of 2024 (1946)
Non-profit (830)
North Carolina (64)
Now hiring (13)
Obesity (44)
Opinion (80)
Parkinson's disease (23)
Peanut (25)
Pennsylvania (13)
People (24478)
Phase I (13536)
Phase II (17931)
Phase III (11416)
Podcasts (13)
Policy (15)
Postmarket research (841)
Preclinical (5719)
Psychedelics (14)
Rare diseases (68)
Real estate (1403)
Recruiting (12)
Regulatory (7907)
Research institute (921)
Resumes & cover letters (16)
Series A (16)
South America (206)
Startups (1954)
Texas (21)
United States (1084)
Vaccines (102)
Washington State (70)
Weight loss (37)
Date
Last 7 days (266)
Last 30 days (1088)
Last 365 days (21933)
2024 (12175)
2023 (22413)
2022 (26822)
2021 (27807)
2020 (23357)
2019 (16225)
2018 (11738)
2017 (13746)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
253,450 Results for "axsome therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories
Axsome Therapeutics, Inc. today announced that it has entered into a settlement agreement with Unichem Laboratories Ltd. (Unichem) resolving patent litigation related to Axsome’s product Sunosi ® (solriamfetol).
June 5, 2024
·
4 min read
Pharm Country
Axsome Therapeutics to Participate in Upcoming June 2024 Investor Conferences
Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced that Axsome will participate in two upcoming investor conferences.
May 30, 2024
·
4 min read
Pharm Country
Axsome Therapeutics to Present at Upcoming May 2024 Investor Conferences
Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences.
May 8, 2024
·
4 min read
Pharm Country
Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month
Axsome Therapeutics, Inc. announced today it is supporting Alzheimer’s & Brain Awareness Month this June.
June 3, 2024
·
6 min read
Business
Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Axsome Therapeutics, Inc., a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system disorders, announced financial results for the first quarter of 2024.
May 6, 2024
·
18 min read
Pharm Country
Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference
Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on Wednesday, March 13, at 9:20 a.m. Eastern Time at the Fontainebleau in Miami Beach, Florida.
March 5, 2024
·
4 min read
Pharm Country
Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During Migraine & Headache Awareness Month
Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, announced today it is joining the migraine advocacy community to raise awareness of unmet patient needs during Migraine & Headache Awareness Month this June.
June 4, 2024
·
7 min read
Business
Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6
Axsome Therapeutics, Inc. announced it will report its financial results for the first quarter of 2024 on Monday, May 6, 2024, before the opening of the U.S. financial markets.
April 10, 2024
·
4 min read
Pharm Country
Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
Axsome Therapeutics, Inc. announced that data from its industry-leading portfolio of novel products for CNS disorders will be presented at the 2024 American Society of Clinical Psychopharmacology Annual Meeting, being held May 28-31, 2024, in Miami Beach, Florida.
May 28, 2024
·
13 min read
Pharm Country
Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
Axsome Therapeutics, Inc. announced five presentations, including two featured oral plenary presentations, on solriamfetol at SLEEP 2024, the 38th annual meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held June 1-5, 2024, in Houston, Texas.
May 29, 2024
·
6 min read
1 of 25,345
Next
